公开(公告)号：US12275728B2

公开(公告)日：2025-04-15

申请号：US18673619

申请日：2024-05-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US20230087118A1

公开(公告)日：2023-03-23

申请号：US17623181

申请日：2020-06-24

Applicant: BIOGEN MA INC.

Inventor： Emily Anne Peterson ,  Ryan Evans ,  Fang Gao ,  Philippe Bolduc ,  Magnus Pfaffenbach ,  Zhili Xin ,  Tricia May-Dracka

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/4985 ,  A61K45/06 ,  C07D519/00 ,  A61K31/519

Abstract: This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US11459324B2

公开(公告)日：2022-10-04

申请号：US16978550

申请日：2019-03-13

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D417/06 ,  C07D471/04

Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.

公开(公告)号：US20220089592A1

公开(公告)日：2022-03-24

申请号：US17421348

申请日：2020-01-17

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Magnus Pfaffenbach ,  Tricia May-dracka ,  Ryan Evans ,  Fang Gao ,  Istvan Enyedy ,  Zhili Xin ,  Philippe Bolduc ,  Emily Anne Peterson

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04

Abstract: This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US20210115020A1

公开(公告)日：2021-04-22

申请号：US17253269

申请日：2019-06-26

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US09944666B2

公开(公告)日：2018-04-17

申请号：US15368454

申请日：2016-12-02

Applicant: BIOGEN MA INC.

Inventor： Kevin M. Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Sha Mi ,  Hairuo Peng ,  Zhaohui Shao ,  Lihong Sun ,  Arthur G. Taveras ,  Zhili Xin ,  Lei Zhang

IPC: C07D401/04 ,  C07D215/38 ,  C07D217/12 ,  A61K31/47 ,  C07F7/08 ,  A61K45/06 ,  C07C229/50 ,  A61K31/196 ,  C07D215/12 ,  A61K31/4545 ,  A61K31/506 ,  C07D295/096 ,  A61K31/495 ,  C07D213/74 ,  A61K31/496 ,  A61K31/551 ,  C07D239/42 ,  C07D241/20 ,  A61K31/497 ,  C07D211/14 ,  A61K31/451 ,  C07D205/04 ,  A61K31/397 ,  C07D401/06 ,  A61K31/4709 ,  C07D491/107 ,  C07D209/52 ,  A61K31/403 ,  C07D451/02 ,  A61K31/439 ,  A61K31/695 ,  C07C233/60 ,  C07D451/14

CPC classification number: C07F7/081 ,  A61K31/195 ,  A61K31/196 ,  A61K31/397 ,  A61K31/403 ,  A61K31/41 ,  A61K31/439 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K45/06 ,  C07C211/38 ,  C07C217/58 ,  C07C229/46 ,  C07C229/50 ,  C07C233/60 ,  C07C233/61 ,  C07C235/66 ,  C07C2102/10 ,  C07C2102/42 ,  C07C2102/44 ,  C07C2102/50 ,  C07C2103/62 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2602/50 ,  C07C2603/62 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/52 ,  C07D211/14 ,  C07D213/74 ,  C07D215/12 ,  C07D215/20 ,  C07D215/38 ,  C07D217/22 ,  C07D239/42 ,  C07D241/20 ,  C07D295/096 ,  C07D401/04 ,  C07D401/06 ,  C07D451/02 ,  C07D451/14 ,  C07D471/08 ,  C07D491/107 ,  C07F7/0805 ,  A61K2300/00

Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

公开(公告)号：US20170158687A1

公开(公告)日：2017-06-08

申请号：US15296601

申请日：2016-10-18

Applicant: BIOGEN MA INC.

Inventor： Kevin M. Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Sha Mi ,  Hairuo Peng ,  Zhaohui Shao ,  Lihong Sun ,  Arthur G. Taveras ,  Deping Wang ,  Zhili Xin ,  Lei Zhang

IPC: C07D451/02 ,  C07D401/06 ,  A61K45/06 ,  A61K31/4725 ,  C07D217/22 ,  A61K31/472

CPC classification number: C07D451/02 ,  A61K31/136 ,  A61K31/196 ,  A61K31/439 ,  A61K31/445 ,  A61K31/46 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5375 ,  A61K31/55 ,  A61K45/06 ,  C07B2200/07 ,  C07C217/22 ,  C07C229/46 ,  C07C229/48 ,  C07C255/59 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/42 ,  C07D209/52 ,  C07D211/34 ,  C07D211/62 ,  C07D217/22 ,  C07D221/22 ,  C07D223/06 ,  C07D295/096 ,  C07D401/06 ,  C07D471/08 ,  Y02A50/401

Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

公开(公告)号：US20240116922A1

公开(公告)日：2024-04-11

申请号：US18269073

申请日：2021-12-21

Applicant: BIOGEN MA INC.

Inventor： Emily Anne Peterson ,  Magnus Pfaffenbach ,  Fang Gao ,  Philippe Bolduc ,  Zhili Xin ,  Ryan Evans

IPC: C07D471/04 ,  A61K45/06 ,  C07D487/04

CPC classification number: C07D471/04 ,  A61K45/06 ,  C07D487/04

Abstract: This disclosure relates to imidazo[1,2-a]pyridinyl derivatives of formula (I), or pharmaceutically acceptable salts thereof, Formula (I) in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The disclosure further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US20230002361A1

公开(公告)日：2023-01-05

申请号：US17623182

申请日：2020-06-24

Applicant: BIOGEN MA INC.

Inventor： Emily Anne Peterson ,  Ryan Evans ,  Fang Gao ,  Philippe Bolduc ,  Magnus Pfaffenbach ,  Zhili Xin

IPC: C07D405/14 ,  C07D471/04 ,  C07D401/12 ,  C07D487/04 ,  C07D519/00

Abstract: This invention relates to 2H-indazole Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US10273234B2

公开(公告)日：2019-04-30

申请号：US14420020

申请日：2013-08-05

Applicant: BIOGEN MA INC.

Inventor： Kevin Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Lihong Sun ,  Zhili Xin ,  Lei Zhang

IPC: C07D471/08 ,  A61K31/122 ,  C07C229/48 ,  C07D223/06 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D211/62 ,  A61K45/06 ,  A61K31/397 ,  A61K31/403 ,  A61K31/44 ,  A61K31/55 ,  A61K31/196 ,  A61K31/40 ,  A61K31/439 ,  A61K31/445 ,  C07C211/38 ,  C07D207/08

Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).